Latest Nura Bio News & Updates

See the latest news and media coverage for Nura Bio. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Nura Bio

Neuroprotective therapies developer

nurabio.com
Headquarters
South San Francisco, United States
Founded year
2018
Company type
Private company
Number of employees
30–50

Last updated

Latest news about Nura Bio

In short: Nura Bio transitioned to a clinical-stage company, raised $68M in Series A funding, and expanded its leadership team.

Company announcements

Nura Bio

Nura Bio appoints C-suite executives

Lahar Mehta, M.D. as Chief Medical Officer and Scott Greenberg as Chief Business Officer to advance clinical pipeline.

Nura Bio

Nura Bio initiates Phase 1 trial for NB-4746

NB-4746 is an oral, brain-penetrant SARM1 inhibitor for neurological diseases like ALS and MS. This marks Nura Bio's transition to a clinical-stage company.

Nura Bio

Nura Bio reports preclinical data on SARM1 inhibitors

Data validates conserved NAD hydrolase inhibition mechanism for neurodegeneration neuroprotection. Publication in Neuron supports First-in-Human trials in early 2023.

Unlock all announcements with a

Media coverage

Business Wire

Nura Bio Reports Preclinical Data Validating a Conserved Mechanism of Inhibition of NAD Hydrolases Implicated in Neurodegeneration in Neuron

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nura Bio Inc., a biopharma company based in South San Francisco, focused on the discovery and development of disease-modifying neuroprotective drugs...

Unlock all articles with a

Never miss news about Nura Bio

Track Nura Bio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Nura Bio competitors & trending companies

Browse news for competitors to Nura Bio and other trending companies.